Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Ionis Pharmaceuticals Inc...

    NASDAQ: IONS · Real-Time Price · USD
    39.66
    1.99 (5.28%)
    At close: Jun 24, 2025, 3:59 PM
    39.64
    -0.06%
    After-hours: Jun 24, 2025, 05:42 PM EDT
    5.28%
    Bid 38.09
    Market Cap 6.31B
    Revenue (ttm) 717.44M
    Net Income (ttm) -458.03M
    EPS (ttm) -2.99
    PE Ratio (ttm) -13.27
    Forward PE -11.77
    Analyst Buy
    Ask 40
    Volume 2,389,021
    Avg. Volume (20D) 1,677,745
    Open 37.87
    Previous Close 37.67
    Day's Range 37.32 - 39.94
    52-Week Range 23.95 - 52.34
    Beta 0.18

    About IONS

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol IONS
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for IONS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Ionis Pharmaceuticals Inc. is scheduled to release its earnings on Jul 31, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    7 months ago
    -7.76%
    Shares of pharmaceutical and healthcare stocks are... Unlock content with Pro Subscription
    9 months ago
    -12.29%
    Ionis Pharmaceuticals shares are trading lower after the company priced its $500.3 million public offering of 11.5 million common shares at $43.50 per share.
    news image

    1 week ago · businesswire.com

    Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026

    CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary, Ph.D., executive vice president and chief development officer, will retire effective J...

    news image

    1 week ago · businesswire.com

    First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

    CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to evaluat...

    news image

    3 weeks ago · zacks.com

    Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?

    Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

    news image

    1 month ago · zacks.com

    Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study

    Late-stage data shows that treatment with an 80mg dose of IONS' Tryngolza achieved a 61% placebo-adjusted reduction in triglyceride levels in six months.

    news image

    1 month ago · businesswire.com

    Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

    CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the Essence study of olezarsen in people with moderate hypertriglyceridemia ...

    news image

    1 month ago · businesswire.com

    Ionis to host 2025 virtual Annual Meeting of Stockholders

    CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2025 virtual Annual Meeting of Stockholders followed by a general corpora...

    news image

    1 month ago · zacks.com

    Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View

    IONS reports better-than-expected first-quarter results. The company raises its sales guidance for 2025 by more than 20% on the back of two new licensing deals.

    news image

    1 month ago · seekingalpha.com

    Ionis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call Transcript

    Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q1 2025 Earnings Conference Call April 30, 2025 11:30 AM ET Company Participants Wade Walke - SVP, IR Brett Monia - Founder, CEO & Director Kyle Jenne - EVP ...

    news image

    1 month ago · benzinga.com

    Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge

    Ionis Pharmaceuticals Inc IONS reported a first-quarter EPS loss of 93 cents on Wednesday, down from a loss of 98 cents, beating the consensus of a $1.12 loss.

    news image

    1 month ago · zacks.com

    Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say

    Although the revenue and EPS for Ionis Pharmaceuticals (IONS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare wit...

    Add to Watchlist